A study to collect follow up clinical data in kidney transplant subjects from two completed studies.

• Conditions: KIDNEY TRANSPLANT; MedDRA version: 14.1Level: LLTClassification code 10023438Term: Kidney transplantSystem Organ Class: 10042613 - Surgical and medical procedures; Therapeutic area: Diseases [C] - Immune System Diseases [C20]

• Registration Number: EUCTR2011-000903-41-IT
• Lead Sponsor: PFIZER INC.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2011-12-23
• Last Update Posted: 28 August 2012

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 110

Inclusion Criteria

Subjects must meet all of the following criteria to be eligible for enrollment into the trial:
1. Subject must meet at least 1 of the following 2 criteria:
a. Subjects have discontinued tofacitinib prior to the planned treatment duration
of study A3921009 (6 months posttransplant) or study A3921030 (12 months posttransplant); or
b. Subjects have not enrolled in the extension studies A3921021 or A3921050.
2. Subjects must be willing and able to provide written informed consent with evidence
of a personally signed and dated informed consent document indicating that the
subject (or a legally acceptable representative) has been informed of all the pertinent
aspects of the study.
Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 94
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 16

Exclusion Criteria

Not applicable.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified